CHUV and theEPFL have discovered a highly potent monoclonal antibody that targets the SARS-CoV-2 spike protein. It is highly effective at neutralising all variants of the virus, including the Delta variant.
This scientific research, published in the prestigious journal *Cell Reports*, paves the way for promising new therapeutic applications as a medicine designed to protect people at risk, such as immunocompromised patients. The new antibody could also be used as part of a combination therapy to reduce the severity of the disease in people infected with SARS-CoV-2.
Read the press release
The research was carried out by teams from the Department of Immunology and Allergology at theCHUV (ITM), led by Prof. Giuseppe Pantaleo and Dr Craig Fenwick, and by the Virology and Genetics Laboratory at theEPFL (UBA), led by Prof. Didier Trono and Dr Priscilla Turelli.
